223 related articles for article (PubMed ID: 9744508)
21. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
[TBL] [Abstract][Full Text] [Related]
22. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
23. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies.
Bielicki D; Karbowniczek M; Sulzyc-Bielicka V; Kładny J; Boer C; Marlicz K; Domagała W
Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
25. Preferential histiotypic expression of CD44-isoforms in human lung cancer.
Wimmel A; Schilli M; Kaiser U; Havemann K; Ramaswamy A; Branscheid D; Kogan E; Schuermann M
Lung Cancer; 1997 Mar; 16(2-3):151-72. PubMed ID: 9152947
[TBL] [Abstract][Full Text] [Related]
26. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis.
Park Y; Kim Y; Lee JH; Lee EY; Kim HS
Arch Pathol Lab Med; 2011 Dec; 135(12):1570-5. PubMed ID: 22129186
[TBL] [Abstract][Full Text] [Related]
28. [Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)].
Skrzypski M; Szymanowska A; Janowicz A; Dziadziuszko R; Ramlau R; Kozielski J; Pilarska-Machowicz A; Dobrzańska Z; Bigda J; Krzakowski M; Jassem E; Jassem J
Pneumonol Alergol Pol; 2002; 70(7-8):353-8. PubMed ID: 12708076
[TBL] [Abstract][Full Text] [Related]
29. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy.
Blanchard P; Quero L; Pacault V; Schlageter MH; Baruch-Hennequin V; Hennequin C
BMC Cancer; 2012 Mar; 12():119. PubMed ID: 22448886
[TBL] [Abstract][Full Text] [Related]
31. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.
Bourhis J; Lubin R; Roche B; Koscielny S; Bosq J; Dubois I; Talbot M; Marandas P; Schwaab G; Wibault P; Luboinski B; Eschwege F; Soussi T
J Natl Cancer Inst; 1996 Sep; 88(17):1228-33. PubMed ID: 8780633
[TBL] [Abstract][Full Text] [Related]
32. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.
O'Callaghan DS; Rexhepaj E; Gately K; Coate L; Delaney D; O'Donnell DM; Kay E; O'Connell F; Gallagher WM; O'Byrne KJ
Eur Respir J; 2015 Dec; 46(6):1762-72. PubMed ID: 26541534
[TBL] [Abstract][Full Text] [Related]
33. Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance.
Jassem E; Bigda J; Dziadziuszko R; Schlichtholz B; Le Roux D; Grodzki T; Rzyman W; Konopa K; Poberezna M; Dobrzańska Z; Skokowski J; Soussi T; Jassem J
Lung Cancer; 2001 Jan; 31(1):17-23. PubMed ID: 11162862
[TBL] [Abstract][Full Text] [Related]
34. Increased circulating activated T-cells in lung cancer.
Tsuyuguchi I; Shiratsuchi H; Fukuoka M
Chest; 1986 May; 89(5):705-8. PubMed ID: 3009097
[TBL] [Abstract][Full Text] [Related]
35. Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation.
Segawa Y; Takigawa N; Mandai K; Maeda Y; Takata I; Fujimoto N; Jinno K
Lung Cancer; 1997 Mar; 16(2-3):229-38. PubMed ID: 9152954
[TBL] [Abstract][Full Text] [Related]
36. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
37. Alloantibodies, autoantibodies, and immune complexes in patients with lung cancer.
Górny MK; Lawniczak M; Jenek R; Słowik-Gabryelska A; Kaczmarek E; Zeromski J
Lung; 1988; 166(2):97-105. PubMed ID: 2835557
[TBL] [Abstract][Full Text] [Related]
38. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue.
Wild CP; Ridanpää M; Anttila S; Lubin R; Soussi T; Husgafvel-Pursiainen K; Vainio H
Int J Cancer; 1995 Jun; 64(3):176-81. PubMed ID: 7622306
[TBL] [Abstract][Full Text] [Related]
39. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.
Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U
Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994
[TBL] [Abstract][Full Text] [Related]
40. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]